Sandoz says Phase III trials show proposed biosimilar pegfilgrastim has similar safety and efficacy as reference product

8 December 2015
biosimilars_samples_large

Sandoz, the generics and biosimilars business of Swiss pharma giant Novartis (NOVN: VX) said late stage trials to compare the safety and efficacy of proposed biosimilar pegfilgrastim with the reference product, Neulasta (pegfilgrastim), met its primary endpoints.

Additional data from the study showed that there were no clinically meaningful differences between the proposed biosimilar pegfilgrastim and the reference product.

Dr Kimberly Blackwell, primary investigator for the study, said: "The positive data from the Protect II study is promising in that it will add to the body of evidence being developed on biosimilars.  These findings could lead to another high-quality supportive care treatment option for physicians and oncology patients."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars